UCLA Medical Center, Los Angeles, CA.
Case Western Reserve School of Medicine, Cleveland, OH.
Spine (Phila Pa 1976). 2018 Sep 1;43(17):E1014-E1023. doi: 10.1097/BRS.0000000000002608.
Systematic review and meta-analysis.
To compare the efficacy of the use of either bisphosphonates or teriparatide on radiographic and functional outcomes of patients that had thoracolumbar spinal fusion.
Controversy exists as to whether bisphosphonates interfere with successful spinal arthrodesis. An alternative osteoporosis medication is teriparatide, a synthetic parathyroid hormone that has an anabolic effect on osteoblast function. To date, there is limited comparative data on the influence of bisphosphonates or teriparatide on spinal fusion.
A systematic search of medical reference databases was conducted for comparative studies on bisphosphonate or teriparatide use after thoracolumbar spinal fusion. Meta-analysis was performed using the random-effects model for heterogeneity. Radiographic outcomes assessed include fusion rates, risk of screw loosening, cage subsidence, and vertebral fracture.
No statistically significant differences were noted between bisphosphonates and control groups regarding fusion rate and risk of screw loosening (fusion: odds ratio [OR] = 2.2, 95% confidence interval [CI]: 0.87-5.56, P = 0.09; loosening: OR = 0.45, 95% CI: 0.14-1.48, P = 0.19). Teriparatide use was associated with higher fusion rates than bisphosphonates (OR = 2.3, 95% CI: 1.55-3.42, P < 0.0001). However, no statistically significant difference was noted between teriparatide and bisphosphonates regarding risk of screw loosening (OR = 0.37, 95% CI: 0.12-1.18, P = 0.09). Lastly, bisphosphonate use was associated with decreased odds of cage subsidence and vertebral fractures compared to controls (subsidence: OR = 0.29, 95% CI 0.11-0.75, P = 0.01; fracture: OR = 0.18, 95% CI 0.07-0.48, P = 0.0007).
Bisphosphonates do not appear to impair successful spinal fusion compared to controls although teriparatide use is associated with higher fusion rates than bisphosphonates. In addition, bisphosphonate use is associated with decreased odds of cage subsidence and vertebral fractures compared to controls that had spinal fusion.
系统评价和荟萃分析。
比较使用双膦酸盐或特立帕肽对接受胸腰椎脊柱融合术的患者的影像学和功能结果的疗效。
关于双膦酸盐是否会干扰成功的脊柱融合存在争议。另一种骨质疏松症药物是特立帕肽,这是一种合成甲状旁腺激素,对成骨细胞功能具有合成代谢作用。迄今为止,关于双膦酸盐或特立帕肽对脊柱融合的影响的比较数据有限。
对医学参考数据库进行了系统搜索,以寻找关于胸腰椎脊柱融合后使用双膦酸盐或特立帕肽的比较研究。使用随机效应模型进行荟萃分析以评估异质性。评估的影像学结果包括融合率、螺钉松动风险、笼沉降和椎体骨折。
在融合率和螺钉松动风险方面,双膦酸盐组与对照组之间没有统计学上的显著差异(融合:优势比[OR] = 2.2,95%置信区间[CI]:0.87-5.56,P = 0.09;松动:OR = 0.45,95%CI:0.14-1.48,P = 0.19)。特立帕肽的使用与更高的融合率相关,而不是双膦酸盐(OR = 2.3,95%CI:1.55-3.42,P < 0.0001)。然而,在螺钉松动风险方面,特立帕肽与双膦酸盐之间没有统计学上的显著差异(OR = 0.37,95%CI:0.12-1.18,P = 0.09)。最后,与对照组相比,双膦酸盐的使用与降低的笼沉降和椎体骨折的几率相关(沉降:OR = 0.29,95%CI 0.11-0.75,P = 0.01;骨折:OR = 0.18,95%CI 0.07-0.48,P = 0.0007)。
与对照组相比,双膦酸盐似乎不会损害成功的脊柱融合,尽管特立帕肽的使用与双膦酸盐相比具有更高的融合率。此外,与对照组相比,双膦酸盐的使用与降低的笼沉降和椎体骨折的几率相关,这些患者接受了脊柱融合术。
3 级。